文献速递功能神经外科

神经元特异性烯醇化酶作为经皮球囊压迫治疗耐药性三叉神经痛响应生物标志物的作用

The Role of Neuron-specific Enolase as a Biomarker of Response in Percutaneous Balloon Compression for Drug-Resistant Trigeminal Neuralgia.
PubMed 文献 · Neurosurgery · 2025-09-11

本研究回顾性分析41例耐药性三叉神经痛患者接受经皮球囊压迫(PBC)的数据,评估血清神经元特异性烯醇化酶(NSE)对术后疼痛复发的预测价值。结果显示术后NSE升高及围手术期NSE增加与复发率降低显著相关,并确定了临床相关截断值。

要点

  • 术后NSE>10.5 ng/mL或围手术期NSE增加>0.5 ng/mL与复发率显著降低相关。
  • 术后NSE水平和围手术期NSE增加是疼痛复发的独立负预测因子。
  • NSE可作为PBC术后风险分层和个体化随访策略的生物标志物。

核心结论

  • NSE是预测耐药性三叉神经痛PBC术后疼痛复发的关键生物标志物。
  • 术后NSE和围手术期NSE增加的临床相关截断值为风险分层提供了实用工具。

研究设计与样本

  • 回顾性分析前瞻性收集的41例耐药性三叉神经痛患者(21男,20女;平均年龄65±13岁)数据,患者于2020年12月至2023年6月接受PBC。
  • 术前和术后收集血清NSE及其他生化参数,评估临床因素包括年龄、性别、TN病程、疼痛类型和侧别、既往手术、球囊形态。
  • 结局包括急性疼痛缓解、复发率及随访时Barrow神经学研究所疼痛评分。

主要发现

  • 41例患者中37例(90.2%)实现急性疼痛缓解。
  • 随访中位19.00(12.75-30.25)个月时BNI疼痛评分较术前显著降低(2.00[1.00-3.00] vs 4.00[4.00-5.00],P<.0001)。
  • 17例(41.5%)观察到疼痛复发。
  • 术后NSE水平较术前显著升高(P=.0301),尤其在无复发患者中(P=.0057)。
  • 术后NSE>10.5 ng/mL或围手术期NSE增加>0.5 ng/mL的患者复发率显著降低(P=.0004和P=.0004)。

关键数值与推荐

  • 术后NSE截断值>10.5 ng/mL与复发率显著降低相关(P=.0004)。
  • 围手术期NSE增加截断值>0.5 ng/mL与复发率显著降低相关(P=.0004)。

临床怎么用

  • 术后监测NSE水平可用于PBC术后疼痛复发的风险分层。
  • 根据NSE截断值识别高风险患者,制定个体化随访策略。

局限性

  • 回顾性研究设计。
  • 样本量较小(41例)。
  • 单中心数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Neuron-specific enolase (NSE) has been identified as a marker of neuronal damage in different clinical conditions. Percutaneous balloon compression (PBC) is a well-established palliative destructive procedure for the treatment of trigeminal neuralgia (TN). The aim of our study was to evaluate the prognostic role of NSE in predicting pain recurrence after PBC for drug-resistant TN. METHODS: We retrospectively analyzed the prospectively collected data of 41 drug-resistant TN patients (21 M, 20 F; mean age 65 ± 13 years) who underwent PBC between December 2020 and June 2023. Serum levels of NSE and other biochemical parameters were collected preoperatively and postoperatively. Clinical factors, including age, sex, TN duration, pain type and side, previous operations, balloon morphology, were assessed. Outcomes included acute pain relief, recurrence rate, and Barrow Neurological Institute pain score at follow-up (FU). RESULTS: Of the 41 patients, 37 (90.2%) achieved acute pain relief. Barrow Neurological Institute pain score was significantly decreased at FU (median 19.00 [12.75-30.25] months) compared with the preoperative one (2.00 [1.00-3.00] and 4.00 [4.00-5.00], respectively; P < .0001). No major complications occurred in the whole cohort. Pain recurrence was observed in 17 patients (41.5%). Postoperative NSE levels significantly increased compared with preoperative levels ( P = .0301) especially in patients without recurrence ( P = .0057). Using receiver operating characteristic curve analysis, the following cutoff values were identified: Patients with postoperative NSE >10.5 ng/mL or perioperative (postoperative minus preoperative) NSE increase >0.5 ng/mL had significantly reduced recurrence rates ( P = .0004 and P = .0004, respectively). Multivariable analyses confirmed postoperative NSE value and perioperative NSE increase as independent negative predictors of pain recurrence ( P = .0420 and P = .0308). CONCLUSION: This study identified NSE as a key biomarker for predicting pain recurrence after PBC for drug-resistant TN. We identified clinically relevant cutoff values for postoperative NSE and perioperative NSE increase, which provide practical tools for risk stratification, allowing personalized FU strategies.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Burattini B, D'Alessandris QG, Rapisarda A, et al. The Role of Neuron-specific Enolase as a Biomarker of Response in Percutaneous Balloon Compression for Drug-Resistant Trigeminal Neuralgia. Neurosurgery. 2025. PMID: 40932275. doi:10.1227/neu.0000000000003724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。